Journal article
Gene Therapy for Hemophilia
Abstract
Hemophilia A and B are X-linked genetic disorders caused by deficiency of the coagulation factors VIII and IX, respectively. Because of the health hazards and costs of current product replacement therapy, much effort is devoted to the development of gene therapy for these disorders. Approaches to gene therapy for the hemophilias include: ex vivo gene therapy in which cells from the intended recipients are explanted, genetically modified to …
Authors
Hortelano G; Chang PL
Journal
Artificial Cells Nanomedicine and Biotechnology, Vol. 28, No. 1, pp. 1–24
Publisher
Taylor & Francis
Publication Date
January 2000
DOI
10.3109/10731190009119782
ISSN
2169-1401